Big Pharma killed vaping
Alleged reason: Vaping endangered nicotine-replacement therapy and medical treatment revenues
Popularity within the vaping community: Medium
"You look at [anti-vaping tobacco-control organizations'] websites, and it says who their donors are. It's all the Big Pharmaceutical companies," Aaron Biebert told me. He's the director of A Billion Lives, a documentary about the various forces arrayed against the industry.
He's not wrong. The American Lung Association lists AstraZeneca and Pfizer as two of its major corporate partners; the American Cancer Society has Merck and Genentech; the American Heart Association, Bristol-Myers Squibb, GlaxoSmithKline, and Pfizer. So on, and so forth.
Some pro-vape advocates claim that the big drug companies (and the health insurance conglomerates, care providers, et al.) are leveraging this cozy financial relationship into a powerful anti-vape lobbying effort. The motive?
Cornering the nicotine-replacement therapy (NRT) market. When you include vapor products, this category is estimated to reach around $20 billion globally by 2023. Without the boost of e-cigarettes' enormous growth, though, the category is "lacklustre" -- particularly in the US. That's partly due to America's decreased smoking rates, and partly to vaping. Thanks to the popularity of vapor products amongst smokers who have failed cessation efforts using offerings like the nicotine patch and gum (the efficacy of both is a source of some debate), or prescription drugs, the enormous cessation market is totally changing.